Available at:

Universitario Santiago De
Compostela Santiago Spain

January 2012

Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versu...

MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study.

Peterfy, Charles
Emery, Paul
Tak, Paul P
Østergaard, Mikkel
DiCarlo, Julie
Otsa, Kati
Navarro Sarabia, Federico
Pavelka, Karel
Bagnard, Marie-Agnes
Gylvin, Lykke Hinsch
Bernasconi, Corrado
Gabriele, Annarita

October 2014

To evaluate changes in structural damage and joint inflammation assessed by MRI following rituximab ...

Rituximab in the treatment of rheumatoid arthritis.

Taylor, P

January 2007

Rheumatoid arthritis is a chronic, disabling condition and the most common form of inflammatory arth...

Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists

Finckh, Axel
Möller, Burkhard
Dudler, Jean
Walker, Ulrich A
Kyburz, Diego
Gabay, Cem
physicians of the Swiss Clinical Quality Management for Rheumato,
physicians of SCQM-RA,

January 2012

Observational studies have suggested that patients with rheumatoid arthritis (RA) who experience ina...

Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists

Finckh, Axel
Möller, Burkhard
Dudler, Jean
Walker, Ulrich A
Kyburz, Diego
Gabay, Cem

January 2012

Observational studies have suggested that patients with rheumatoid arthritis (RA) who experience ina...

Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists

Finckh, Axel
Möller, Burkhard
Dudler, Jean
Walker, Ulrich A
Kyburz, Diego
Gabay, Cem

January 2012

BACKGROUND: Observational studies have suggested that patients with rheumatoid arthritis (RA) who ex...

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies

Keystone, E.
Emery, P.
Peterfy, C.G.
Tak, P.P.
Cohen, S.
Genovese, M.C.
Dougados, M.
Burmester, G.R.
Greenwald, M.
Kvien, T.K.
Williams, S.
Hagerty, D.
Cravets, M.W.
Shaw, T.

January 2009

OBJECTIVE: To determine if treatment with a B cell-targeted therapy can inhibit the progression of s...

Effectiveness of a Third Tumor Necrosis Factor-alpha-blocking Agent Compared with Rituximab After Failure of 2 TNF-blocking Agents in Rheumatoid Arthritis

Blom, M.
Kievit, W.
Donders, A.R.T.
Broeder, A. den
Straten, V.H.
Kuper, I.
Visser, H.
Jansen, T.L.Th.A.
Brus, H.L.
Branten, A.J.W.
Laar, M.A. van der
Riel, P.L. van

January 2011

Item does not contain fulltextOBJECTIVE: To compare the effectiveness of a third tumor necrosis fact...

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents

Finckh, Axel
Ciurea, Adrian
Brulhart, Laure Sophie
Kyburz, Diego
Möller, Burkhard
Dehler, Silvia
Revaz, Sylvie
Dudler, Jean
Gabay, Cem
Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis

January 2007

Objective: Patients with rheumatoid arthritis (RA) in whom the response to anti-tumor necrosis facto...

Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study

Emery, P
Gottenberg, J E
Rubbert-Roth, A
Sarzi-Puttini, P
Choquette, D
Martínez Taboada, V M
Barile-Fabris, L
Moots, R J
Ostor, A
Andrianakos, A
Gemmen, E
Mpofu, C
Chung, C
Gylvin, L Hinsch
Finckh, Axel

January 2015

To compare the effectiveness of rituximab versus an alternative tumour necrosis factor (TNF) inhibit...

Effectiveness of a Third Tumor Necrosis Factor-alpha-blocking Agent Compared with Rituximab After Failure of 2 TNF-blocking Agents in Rheumatoid Arthritis

Blom, M.
Kievit, W.
Donders, A.R.T.
Broeder, A. den
Straten, V.H.
Kuper, I.
Visser, H.
Jansen, T.L.Th.A.
Brus, H.L.
Branten, A.J.W.
Laar, M.A. van der
Riel, P.L. van

January 2011

OBJECTIVE: To compare the effectiveness of a third tumor necrosis factor-alpha (TNF-alpha)-blocking ...

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

Finckh, Axel
Ciurea, A.
Brulhart, L.
Moller, B.
Walker, U. A.
Courvoisier, Delphine
Kyburz, D.
Dudler, J.
Gabay, Cem

January 2010

BACKGROUND: Patients with rheumatoid arthritis (RA) with an inadequate response to TNF antagonists (...

MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study

Peterfy, Charles
Emery, Paul
Tak, Paul P.
Østergaard, Mikkel
Dicarlo, Julie
Otsa, Kati
Navarro Sarabia, Federico
Pavelka, Karel
Bagnard, Marie-Agnes
Gylvin, Lykke Hinsch
Bernasconi, Corrado
Gabriele, Annarita

January 2016

To evaluate changes in structural damage and joint inflammation assessed by MRI following rituximab ...

MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study

Peterfy, Charles
Emery, Paul
Tak, Paul P.
Østergaard, Mikkel
Dicarlo, Julie
Otsa, Kati
Navarro Sarabia, Federico
Pavelka, Karel
Bagnard, Marie-Agnes
Gylvin, Lykke Hinsch
Bernasconi, Corrado
Gabriele, Annarita

January 2016

To evaluate changes in structural damage and joint inflammation assessed by MRI following rituximab ...

Correspondence to

Universitario Santiago De
Compostela Santiago Spain

January 2012

Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versu...

Correspondence to

Universitario Santiago De
Compostela Santiago Spain

January 2012

Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versu...

MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study.

Peterfy, Charles
Emery, Paul
Tak, Paul P
Østergaard, Mikkel
DiCarlo, Julie
Otsa, Kati
Navarro Sarabia, Federico
Pavelka, Karel
Bagnard, Marie-Agnes
Gylvin, Lykke Hinsch
Bernasconi, Corrado
Gabriele, Annarita

October 2014

To evaluate changes in structural damage and joint inflammation assessed by MRI following rituximab ...

Rituximab in the treatment of rheumatoid arthritis.

Taylor, P

January 2007

Rheumatoid arthritis is a chronic, disabling condition and the most common form of inflammatory arth...

Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists

Finckh, Axel
Möller, Burkhard
Dudler, Jean
Walker, Ulrich A
Kyburz, Diego
Gabay, Cem
physicians of the Swiss Clinical Quality Management for Rheumato,
physicians of SCQM-RA,

January 2012

Observational studies have suggested that patients with rheumatoid arthritis (RA) who experience ina...

Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists

Finckh, Axel
Möller, Burkhard
Dudler, Jean
Walker, Ulrich A
Kyburz, Diego
Gabay, Cem

January 2012

Observational studies have suggested that patients with rheumatoid arthritis (RA) who experience ina...

Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists

Finckh, Axel
Möller, Burkhard
Dudler, Jean
Walker, Ulrich A
Kyburz, Diego
Gabay, Cem

January 2012

BACKGROUND: Observational studies have suggested that patients with rheumatoid arthritis (RA) who ex...

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies

Keystone, E.
Emery, P.
Peterfy, C.G.
Tak, P.P.
Cohen, S.
Genovese, M.C.
Dougados, M.
Burmester, G.R.
Greenwald, M.
Kvien, T.K.
Williams, S.
Hagerty, D.
Cravets, M.W.
Shaw, T.

January 2009

OBJECTIVE: To determine if treatment with a B cell-targeted therapy can inhibit the progression of s...

Effectiveness of a Third Tumor Necrosis Factor-alpha-blocking Agent Compared with Rituximab After Failure of 2 TNF-blocking Agents in Rheumatoid Arthritis

Blom, M.
Kievit, W.
Donders, A.R.T.
Broeder, A. den
Straten, V.H.
Kuper, I.
Visser, H.
Jansen, T.L.Th.A.
Brus, H.L.
Branten, A.J.W.
Laar, M.A. van der
Riel, P.L. van

January 2011

Item does not contain fulltextOBJECTIVE: To compare the effectiveness of a third tumor necrosis fact...

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents

Finckh, Axel
Ciurea, Adrian
Brulhart, Laure Sophie
Kyburz, Diego
Möller, Burkhard
Dehler, Silvia
Revaz, Sylvie
Dudler, Jean
Gabay, Cem
Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis

January 2007

Objective: Patients with rheumatoid arthritis (RA) in whom the response to anti-tumor necrosis facto...

Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study

Emery, P
Gottenberg, J E
Rubbert-Roth, A
Sarzi-Puttini, P
Choquette, D
Martínez Taboada, V M
Barile-Fabris, L
Moots, R J
Ostor, A
Andrianakos, A
Gemmen, E
Mpofu, C
Chung, C
Gylvin, L Hinsch
Finckh, Axel

January 2015

To compare the effectiveness of rituximab versus an alternative tumour necrosis factor (TNF) inhibit...

Effectiveness of a Third Tumor Necrosis Factor-alpha-blocking Agent Compared with Rituximab After Failure of 2 TNF-blocking Agents in Rheumatoid Arthritis

Blom, M.
Kievit, W.
Donders, A.R.T.
Broeder, A. den
Straten, V.H.
Kuper, I.
Visser, H.
Jansen, T.L.Th.A.
Brus, H.L.
Branten, A.J.W.
Laar, M.A. van der
Riel, P.L. van

January 2011

OBJECTIVE: To compare the effectiveness of a third tumor necrosis factor-alpha (TNF-alpha)-blocking ...

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

Finckh, Axel
Ciurea, A.
Brulhart, L.
Moller, B.
Walker, U. A.
Courvoisier, Delphine
Kyburz, D.
Dudler, J.
Gabay, Cem

January 2010

BACKGROUND: Patients with rheumatoid arthritis (RA) with an inadequate response to TNF antagonists (...

MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study

Peterfy, Charles
Emery, Paul
Tak, Paul P.
Østergaard, Mikkel
Dicarlo, Julie
Otsa, Kati
Navarro Sarabia, Federico
Pavelka, Karel
Bagnard, Marie-Agnes
Gylvin, Lykke Hinsch
Bernasconi, Corrado
Gabriele, Annarita

January 2016

To evaluate changes in structural damage and joint inflammation assessed by MRI following rituximab ...

MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study

Peterfy, Charles
Emery, Paul
Tak, Paul P.
Østergaard, Mikkel
Dicarlo, Julie
Otsa, Kati
Navarro Sarabia, Federico
Pavelka, Karel
Bagnard, Marie-Agnes
Gylvin, Lykke Hinsch
Bernasconi, Corrado
Gabriele, Annarita

January 2016

To evaluate changes in structural damage and joint inflammation assessed by MRI following rituximab ...

Correspondence to

Universitario Santiago De
Compostela Santiago Spain

January 2012

Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versu...

Correspondence to

Universitario Santiago De
Compostela Santiago Spain

January 2012

Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versu...

MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study.

Peterfy, Charles
Emery, Paul
Tak, Paul P
Østergaard, Mikkel
DiCarlo, Julie
Otsa, Kati
Navarro Sarabia, Federico
Pavelka, Karel
Bagnard, Marie-Agnes
Gylvin, Lykke Hinsch
Bernasconi, Corrado
Gabriele, Annarita

October 2014

To evaluate changes in structural damage and joint inflammation assessed by MRI following rituximab ...

Rituximab in the treatment of rheumatoid arthritis.

Taylor, P

January 2007

Rheumatoid arthritis is a chronic, disabling condition and the most common form of inflammatory arth...

Abstract

Extracted data

Available at:

Abstract

Extracted data

Related items

Related items